Zobrazeno 1 - 10
of 317
pro vyhledávání: '"Ross Baker"'
Autor:
Kerry Kuluski, Maaike Asselbergs, Ross Baker, Katharina (Kathy) Kovacs Burns, Frances Bruno, Marianne Saragosa, Anne MacLaurin, Virginia Flintoft, Lianne Jeffs
Publikováno v:
Health Expectations, Vol 27, Iss 1, Pp n/a-n/a (2024)
Abstract Introduction Creating safer care is a high priority across healthcare systems. Despite this, most systems tend to focus on mitigating past harm, not creating proactive solutions. Managers and staff identify safety threats often with little i
Externí odkaz:
https://doaj.org/article/41519110153a469bb2cfc2fa125739f6
Autor:
Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie-Laure Risse, Philippe Moreau
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free
Externí odkaz:
https://doaj.org/article/8e61c702b45741d49f7cd38053f87ec5
Autor:
Ecenur Guder Arslan, Kwee Yong, Thomas Martın, Meletios Dımopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Facon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang-Ki Mın, Philippe Moreau
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S14-S15 (2023)
Objective: Isatuximab (Isa, anti-CD38 monoclonal antibody) is approved in combination with carfilzomib (K) and dexamethasone (d), for relapsed multiple myeloma (MM) patients (pts) after ≥1 prior therapy. Final progression free survival (PFS) analys
Externí odkaz:
https://doaj.org/article/5bf335a963004c8aafd92c9904acdefe
Autor:
Thierry Facon, Philippe Moreau, Ross Baker, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Nicole M. Armstrong, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, Thomas Martin
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
Patients with multiple myeloma (MM) who experience early relapse within 12 months of therapy initiation are considered functional high-risk and represent an unmet need, needing better therapies to improve outcomes. The final IKEMA (clinicaltrials gov
Externí odkaz:
https://doaj.org/article/a859ab568ace4b82af9a728c2589dbf0
Autor:
Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie-Laure Risse, Philippe Moreau
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/bbebf16ae9ae4bdab06ac313f9c5c8ac
Autor:
Marcelo Capra, Thomas Martin, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios Dimopoulos
Publikováno v:
Haematologica, Vol 107, Iss 6 (2021)
Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomi
Externí odkaz:
https://doaj.org/article/07fc5002e7574551bc21eb0eddf6cde5
Autor:
Kenneth Rockwood, Holly Witteman, Jayna Holroyd-Leduc, Joanie Sims Gould, Andrew P Costa, Mohammad Hajizadeh, Veronique Boscart, George Heckman, Paul Stolee, Jacobi Elliott, Heather M Hanson, Sara Mallinson, Olga Theou, Anik MC Giguere, Ross Baker, Catherine Burns, Kerry Byrne, Judith Carson, Justine Giosa, Kelly Grindrod, Stephanie Hastings, Ayse Kuspinar, Samantha Meyer, Josephine McMurray, Phyllis Puchyr, Peter Puchyr
Publikováno v:
BMJ Open, Vol 11, Iss 5 (2021)
Introduction Older Canadians living with frailty are high users of healthcare services; however, the healthcare system is not well designed to meet the complex needs of many older adults. Older persons look to their primary care practitioners to asse
Externí odkaz:
https://doaj.org/article/b8831ecd62044436b2604e16bc2c3460
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234048 (2020)
BACKGROUND:Warfarin is an anticoagulant medication proven effective in the initial treatment and secondary prevention of venous thromboembolism. Anti-Xa direct oral anticoagulants are alternatives to warfarin; however there is limited data assessing
Externí odkaz:
https://doaj.org/article/8ee6c3fe40ff4f79bf67efdd8e338719
Autor:
Walter Wodchis, Ross Baker, Carolyn Steele Gray, Kerry Kuluski, Shaw James, Kirst Marit, Embuldeniya Gaya
Publikováno v:
International Journal of Integrated Care, Vol 19, Iss 4 (2019)
Introduction: While integrated care programs are proliferating around the world, rigorous measurement and evaluation of the intended and unintended effects of these programs are rare outside of the context of specific research programs. There are a n
Externí odkaz:
https://doaj.org/article/c7257158f2834720910329bb44c829b9
Autor:
Susan Chatwood, Francois Paulette, Ross Baker, Astrid Eriksen, Ketil Lenert Hansen, Heidi Eriksen, Vanessa Hiratsuka, Josée Lavoie, Wendy Lou, Ian Mauro, James Orbinski, Nathalie Pabrum, Hanna Retallack, Adalsteinn Brown
Publikováno v:
International Journal of Circumpolar Health, Vol 74, Iss 0, Pp 1-9 (2015)
With the recognized need for health systems’ improvements in the circumpolar and indigenous context, there has been a call to expand the research agenda across all sectors influencing wellness and to recognize academic and indigenous knowledge thro
Externí odkaz:
https://doaj.org/article/f50fd38864f442abaa4ed85add6ff3e3